Functions of Galectin-3 and Its Role in Fibrotic Diseases

Akahani, 1997, Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family, Cancer Res, 57, 5272

Aplin, 1998, Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins, Pharmacol Rev, 50, 197

10.1016/j.jacc.2013.07.087

10.1016/j.cytogfr.2004.03.006

10.1161/ATVBAHA.112.300569

10.1097/MEG.0b013e328337d602

10.1007/s00894-010-0832-3

10.1093/qjmed/hcr235

10.1165/rcmb.2013-0025OC

10.3748/wjg.v20.i10.2515

10.1111/j.1742-4658.2007.05806.x

Danella Polli, 2013, Monocyte migration driven by galectin-3 occurs through distinct mechanisms involving selective interactions with the extracellular matrix, ISRN Inflamm, 2013, 259256, 10.1155/2013/259256

10.1097/TP.0b013e318242f40a

10.3109/14653249.2011.637668

10.1023/A:1018554124545

10.1126/scitranslmed.3004700

10.1002/hep.26898

Fukumori, 2003, CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis, Cancer Res, 63, 8302

10.1158/0008-5472.CAN-04-0336

Gao, 2014, Galectin-3 induces cell migration via a calcium-sensitive MAPK/ERK1/2 pathway, Oncotarget, 5, 2077, 10.18632/oncotarget.1786

10.1016/S0092-8674(00)81279-9

10.1111/1751-2980.12126

10.1124/jpet.114.213520

10.1007/s10238-013-0229-6

10.1073/pnas.0511167103

10.2353/ajpath.2008.070726

10.1124/jpet.112.194142

10.1016/j.jacc.2012.04.053

10.1038/jid.2008.276

10.1093/glycob/4.1.5

10.1126/science.1176009

10.1007/BF00731303

10.1111/j.1476-5381.2012.01847.x

10.1152/ajpgi.00257.2011

10.1016/j.prp.2008.09.001

10.1002/(SICI)1096-9896(199607)179:3<309::AID-PATH572>3.0.CO;2-D

10.1186/1465-9921-11-31

10.1073/pnas.0605669103

10.1007/s10067-013-2346-8

10.1124/jpet.114.213009

10.1016/j.carpath.2013.01.003

10.1371/journal.pone.0082478

10.1358/dnp.2007.20.7.1149628

10.1042/BJ20031300

10.1038/nrneph.2011.149

10.1152/ajpheart.00747.2008

10.1007/s00392-010-0125-y

10.1093/eurjhf/hfr151

10.1016/j.bbrc.2014.04.068

10.4049/jimmunol.180.4.2650

10.1164/rccm.201106-0965OC

10.1074/jbc.M209673200

10.1152/ajpcell.00230.2013

10.1074/jbc.M112.426445

10.1007/s11033-010-0594-0

10.1124/jpet.112.200881

10.2353/ajpath.2008.080380

10.1016/S0002-9440(10)64959-0

10.1016/j.cell.2010.02.029

10.1189/jlb.1204702

10.2332/allergolint.O-06-449

10.1023/B:GLYC.0000014082.99675.2f

10.1152/ajprenal.00326.2010

10.1126/science.1102109

10.1124/jpet.113.210138

10.1183/09031936.00073005

Pricci, 2000, Role of galectin-3 as a receptor for advanced glycosylation end products, Kidney Int Suppl, 77, S31, 10.1046/j.1523-1755.2000.07706.x

10.4049/jimmunol.179.11.7800

10.1164/rccm.200406-788PP

10.1586/14779072.2013.839942

10.4049/jimmunol.165.4.2156

Sato, 1992, Binding specificity of a baby hamster kidney lectin for H type I and II chains, polylactosamine glycans, and appropriately glycosylated forms of laminin and fibronectin, J Biol Chem, 267, 6983, 10.1016/S0021-9258(19)50525-7

Sato, 1994, Regulation of secretion and surface expression of Mac-2, a galactoside-binding protein of macrophages, J Biol Chem, 269, 4424, 10.1016/S0021-9258(17)41797-2

10.1161/01.CIR.0000147181.65298.4D

Shibata, 2005, Impact of nuclear galectin-3 expression on histological differentiation and vascular invasion in patients with esophageal squamous cell carcinoma, Oncol Rep, 13, 235

10.3748/wjg.v18.i28.3635

10.4049/jimmunol.176.2.778

Sureshbabu, 2011, Relative roles of TGF-β and IGFBP-5 in idiopathic pulmonary fibrosis, Pulm Med, 2011, 517687, 10.1155/2011/517687

10.1038/nrneph.2014.14

10.3899/jrheum.110755

10.2174/09298673113209990163

10.1186/1755-1536-5-11

10.1371/journal.pone.0075361

10.1124/jpet.113.208223

10.1016/j.febslet.2013.10.034

10.1159/000355846

10.1073/pnas.93.13.6737

10.1017/S1462399408000719

10.1161/CIRCHEARTFAILURE.112.971168

10.1016/S0002-9440(10)63255-5